AIM ImmunoTech Inc.
AIM
$0.23
$0.00-0.09%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.00% | 37.50% | -53.33% | -25.71% | -50.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.00% | 37.50% | -53.33% | -25.71% | -50.00% |
| Cost of Revenue | -50.00% | -60.00% | 471.43% | 750.00% | 25.00% |
| Gross Profit | 40.00% | 200.00% | -150.00% | -255.56% | -64.29% |
| SG&A Expenses | 98.05% | -29.78% | -55.20% | -41.60% | -42.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.50% | -38.16% | -49.61% | -45.34% | -28.66% |
| Operating Income | -32.77% | 38.49% | 49.58% | 45.49% | 28.37% |
| Income Before Tax | -35.58% | 18.41% | 30.03% | 11.24% | -52.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.58% | 18.41% | 30.03% | 11.24% | -52.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.58% | 18.41% | 30.03% | 11.24% | -52.18% |
| EBIT | -32.77% | 38.49% | 49.58% | 45.49% | 28.37% |
| EBITDA | -28.28% | 38.70% | 49.77% | 45.93% | 35.95% |
| EPS Basic | 93.99% | 86.81% | 84.51% | 75.55% | -6.01% |
| Normalized Basic EPS | 93.97% | 86.91% | 84.01% | 56.15% | -10.79% |
| EPS Diluted | 93.99% | 86.81% | 84.51% | 75.55% | -6.01% |
| Normalized Diluted EPS | 93.97% | 86.91% | 84.01% | 56.15% | -10.79% |
| Average Basic Shares Outstanding | 2,154.54% | 518.71% | 351.78% | 262.98% | 43.56% |
| Average Diluted Shares Outstanding | 2,154.54% | 518.71% | 351.78% | 262.98% | 43.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |